← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Circumvent Pharmaceuticals, Inc.
Portland, CA
$5,147,318
Total funding
4
Grants
Funding over time
peak $2.3M · FY2017–25$2.5M$1.9M$1.3M$625K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,147,318 · 4
By mechanism
R44$4,136,457 · 1
R43$706,074 · 2
R41$304,787 · 1
Investigators at Circumvent Pharmaceuticals, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Development of N-tert-(Butyl)hydroxylamine (NtBuHA) as a therapeutic agent for treating Infantile Neuronal Ceroid Lipofuscinosis (INCL)$1,449,910
R44 · FY2022 · NS
Development of N-tert-(Butyl)hydroxylamine (NtBuHA) as a therapeutic agent for treating Infantile Neuronal Ceroid Lipofuscinosis (INCL)$1,441,757
R44 · FY2021 · NS
Development of N-tert-(butyl)hydroxylamine (NtBuHA) as a therapeutic agent for treating CLN1 Batten Disease$1,244,790
R44 · FY2025 · NS
Alzheimer's Disease: simultaneous modulation of NMDAR, BACE1, APP and Fyn activity by palmitoylation-targeting CIRC825$507,284
R43 · FY2021 · AG
Development of a protein palmitoylation assay to monitor treatment of CLN1 Batten Disease$304,787
R41 · FY2021 · HD
Development of N-tert-(Butyl)hydroxylamine (NtBuHA) as a therapeutic agent for treating Infantile Neuronal Ceroid Lipofuscinosis (INCL)$198,790
R43 · FY2017 · NS